Health Care · Pharmaceutical Preparations

UTHR UNITED THERAPEUTICS Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1082554342 filings

UTHR at a glance

UNITED THERAPEUTICS Corp (UTHR, SEC CIK 1082554) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion (up 10.6% from FY2024) and net income of $1.3 billion. Diluted EPS was $27.86.
  • As of September 30, 2026, 40 institutional investment managers tracked by SignalX reported holding UNITED THERAPEUTICS Corp (UTHR) shares worth $10.2 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by MAHON PAUL A on November 19, 2026 of 440 shares at $554.73 per share.
  • In the last 90 days, UTHR insiders reported 0 open-market purchases ($0) and 870 open-market sales ($343.3M) on Form 4, a net sale of $343.3M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$3.2B
+10.6% vs prior year
Insiders · 90 days
0 buys · 870 sells
Net −$343.3M
13F holders
40 funds
$10.2B · −1 vs prior quarter
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $832.5M, up from $799.5M YoY, a $33.0M increase
  • Total Tyvaso $503.8M, up 5% YoY; Tyvaso DPI $378.5M best performer, Nebulized Tyvaso $125.3M, down 12%
  • R&D expense $279.2M vs $127.5M YoY, driven by Thymmune acquisition and organ projects
  • Cash and investments $3,535.7M at September 30, down $1,161.3M from December 31; operating cash flow $1,083.4M
  • $3.0B share-repurchase authorization fully utilized; near-term growth expected from Tyvaso DPI, PH-ILD, ralinepag and IPF approval opportunities, with competition and pricing pressure headwinds

Risk Factors

  • New regulatory risk: FDA’s September 2026 OAI classification for sole-source ScinoPharm could delay ralinepag approval beyond June 24, 2027
  • Most material operational update: Yutrepia competition reduced Nebulized Tyvaso sales, with nine-month revenue down $81.5 million
  • Legal risk: 340B contract-pharmacy policy remains subject to potential HRSA or state enforcement despite favorable appellate rulings
  • Near-term reimbursement risk: Medicare Part D discounts increased to 10% initial-phase and 20% catastrophic-phase reductions
  • Financial risk: Cash and investments declined 25% to $3,535.7 million after $3.0 billion share repurchases热在线精品

AI summary of the UTHR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 earnings release for the quarter ended September 30, 2026
  • Detailed financial results and management commentary in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $832.5M, up 4%, led by Tyvaso DPI $378.5M, up 13%, and Orenitram $145.0M, up 11%
  • Net income $258.6M, down 24%, as R&D surged 119% to $279.2M, primarily from Thymmune IPR&D and organ-development projects
Filed Oct 22, 2026Full analysis →

Item 8.01: Other Events

  • $2.0 billion share repurchase authorization approved, signaling substantial capital return to shareholders
  • Program runs through October 21, 2027, providing flexibility on repurchase timing

Item EX-99.1: Item EX-99.1

  • New $2 billion repurchase authorization available through October 21, 2027
  • Capital-return capacity signals management confidence and prioritizes buybacks alongside long-term investment
Filed Oct 14, 2026Full analysis →

Item 8.01: Other Events

  • Liquidia settlement provides UTHR $330.4M, including $185M for past Yutrepia PH-ILD sales and $145.4M through April 2027
  • Yutrepia must remove its PH-ILD indication, restricting Liquidia’s marketing, sales, payer access and related clinical-trial activity

Item EX-99.1: Item EX-99.1

  • Liquidia owes UTC $330.4M total: $185M immediate damages plus $145.4M for future PH-ILD sales
  • UTC pays Liquidia $10M to resolve one proceeding, making net stated cash consideration to UTC $320.4M

AI summaries of UTHR 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for UTHR

Don't miss the next UTHR filing

  • Alerts as it files. A push when UTHR files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut UTHR, by share count.
  • Ask anything. An AI agent that reads every UTHR filing and answers with sources.

UTHR alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
MAHON PAUL AMNov 19, 2026$146.03
MAHON PAUL ASellNov 19, 2026$554.73
MAHON PAUL ASellNov 19, 2026$556.07
MAHON PAUL ASellNov 19, 2026$557.46
MAHON PAUL ASellNov 19, 2026$558.49
MAHON PAUL ASellNov 19, 2026$559.50
MAHON PAUL ASellNov 19, 2026$560.63
MAHON PAUL ASellNov 19, 2026$561.78

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.9B$3.2B
Gross Profit-$2.6B$2.8B
Operating Income-$1.4B$1.5B
Net Income-$1.2B$1.3B
Gross Margin-89.2%87.9%
Op. Margin-47.9%46.9%
Net Margin-41.5%41.9%
Balance Sheet
Total Assets$7.2B$7.4B$7.9B
Equity$6.0B$6.4B$7.1B
ROE-18.5%18.8%
Per Share
EPS-$24.64$27.86
Cash Flow
Operating CF-$1.3B$1.6B
CapEx-$246.5M$520.5M

Source: XBRL data in UNITED THERAPEUTICS Corp (UTHR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate UTHR share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
UTHR shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202640$10.25B
Q2 202641$10.20B
Q1 202640$11.55B
Q4 202537$9.44B
Q3 202536$8.82B
Q2 202535$5.84B
Q1 202534$4.54B
Q4 202430$4.95B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 293 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

UTHR filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
4Nov 19, 2026--
4Nov 18, 2026--
4Nov 17, 2026--
4Nov 16, 2026--
4Nov 13, 2026--
4Nov 12, 2026--
4Nov 12, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 10, 2026--
4Nov 9, 2026--
4Nov 6, 2026--
4Nov 6, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
4Nov 5, 2026--
10-QNov 4, 2026Analysis
8-KNov 4, 2026Analysis-
4Nov 4, 2026--
4Nov 3, 2026--
4Nov 2, 2026--
4Oct 30, 2026--
4Oct 29, 2026--
4Oct 28, 2026--

Related Health Care companies

All Health Care →

UTHR SEC filings: frequently asked questions

Are UTHR insiders buying or selling?

In the last 90 days, UNITED THERAPEUTICS Corp (UTHR) officers, directors and 10% owners reported no open-market purchases and 870 open-market sales worth $343.3 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold UTHR stock?

As of September 30, 2026, the largest UNITED THERAPEUTICS Corp (UTHR) holders among the 13F filers tracked by SignalX were BlackRock ($3.0 billion), State Street Corp ($1.1 billion), Vanguard Capital Management LLC ($1.0 billion), Vanguard Portfolio Management LLC ($1.0 billion), Renaissance Technologies LLC ($908.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was UTHR's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), UNITED THERAPEUTICS Corp (UTHR) reported revenue of $3.2 billion (up 10.6% from FY2024) and net income of $1.3 billion. Diluted EPS was $27.86. The figures come from the XBRL data in the 10-K.

What did UTHR report in its latest 8-K?

UNITED THERAPEUTICS Corp (UTHR) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 earnings release for the quarter ended September 30, 2026.

What are the latest UTHR SEC filings?

UNITED THERAPEUTICS Corp (UTHR) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 19, 2026.

What is UTHR's SEC CIK number?

UNITED THERAPEUTICS Corp (UTHR)'s SEC Central Index Key (CIK) is 1082554. EDGAR lists every UTHR filing under that number.

Ask anything about UTHR

The research agent reads UTHR's filings, financials, insider trades and 13F holders, then answers with sources.